Ann Acad Med Singap
-
Ann Acad Med Singap · Dec 2024
Intrapleural fibrinolytic therapy for pleural infections: Outcomes from a cohort study.
Pleural infections are a significant cause of mortality. Intrapleural fibrinolytic therapy (IPFT) utilising alteplase and dornase is a treatment option for patients unsuitable for surgery. The optimal dose of alteplase is unknown, and factors affecting treatment success in an Asian population are unclear. We sought to determine the factors affecting treatment success in Tan Tock Seng Hospital, Singapore and evaluate the efficacy of lower doses of IPFT. ⋯ Lower starting doses of alteplase remain effective in the treatment of pleural infection. Early IPFT may result in better outcomes.
-
Ann Acad Med Singap · Dec 2024
Epidemiology of paediatric intensive care unit admissions, deaths and organ donation candidacy: A single-centre audit.
There are limited reports on the epidemiology of paediatric intensive care unit (PICU) admissions, deaths and organ donation candidacy. We aimed to describe PICU admission characteristics and outcomes, determine risk factors for mortality, and perform an independent assessment of missed organ donation opportunities. ⋯ In this single-centre audit, comorbidities, PIM 3 score and functional impairment were associated with mortality. Efforts are needed to improve paediatric organ donation rates.
-
Ann Acad Med Singap · Dec 2024
Radiologic placement of totally implantable venous access devices: Outcomes and complications from a large oncology cohort.
Totally implantable venous access devices (TIVADs) or ports are increasingly used in oncology settings to provide long-term, easy venous access. This study reports our experience and results with 1180 cases in Singapore. ⋯ TIVAD implantation via the jugular vein under radiological guidance provides a safe, reliable and convenient means of long-term venous access in oncology patients. By sharing our experience and acceptable outcomes from a large oncology cohort, we aim to increase the awareness and adoption of TIVAD usage in oncology patients, especially in Asia.